TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Instagram Outage Disrupts Thousands of U.S. Users 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
COLORADO SPRINGS, Colo., Oct. 06, 2016 -- The Spectranetics Corporation (Nasdaq:SPNC) today announced that the Company will release third quarter 2016 financial results after the market close on Thursday, October 27, 2016. Company management will host a conference call beginning at 2:30 p.m. Mountain Time (4:30 p.m. Eastern Time) to discuss the results. The dial-in for the conference call is (877) 561-2747 for domestic callers or (973) 409-9689 for international callers, and the Conference ID is 89698306. There will also be a live webcast of the call on the investor relations section of the Company’s website at www.spectranetics.com, which will be available on the Company’s website for 14 days following the completion of the call.
Additionally, the Company announced that it will host a physician panel and Q&A session with Company management at the Transcatheter Cardiovascular Therapeutics conference in Washington, D.C., on November 2, 2016, following the release of the ILLUMENATE Pivotal study. The event will begin at 10:00 a.m. Eastern Time. Space will be limited and you must RSVP to [email protected] to reserve a seat. There will also be a live webcast of the event on the investor relations section of the Company’s website at www.spectranetics.com, which will be available on the Company’s website for 14 days following the event.
About Spectranetics
The Spectranetics Corporation develops, manufactures, markets and distributes medical devices used in minimally invasive procedures within the cardiovascular system. The Company's products are available in over 65 countries and are used to treat arterial blockages in the heart and legs and in the removal of pacemaker and defibrillator leads.
The Company's Vascular Intervention (VI) products include a range of laser catheters for ablation of blockages in arteries above and below the knee, the AngioSculpt scoring balloon used in both peripheral and coronary procedures, and the Stellarex drug-coated balloon peripheral angioplasty platform, which received European CE mark approval in December 2014. The Company also markets support catheters to facilitate crossing of peripheral and coronary arterial blockages, and retrograde access and guidewire retrieval devices used in the treatment of peripheral arterial blockages, including chronic total occlusions. The Company markets aspiration and cardiac laser catheters to treat blockages in the heart.
The Lead Management (LM) product line includes excimer laser sheaths, dilator sheaths, mechanical sheaths and accessories for the removal of pacemaker and defibrillator cardiac leads.
For more information, visit www.spectranetics.com.
Investor Relations Contacts Zach Stassen [email protected] (719) 447-2292 Michaella Gallina [email protected] (719) 447-2417
